ADA 2026 GLP-1 Pipeline: Retatrutide, CagriSema, Orforglipron The next wave of incretin therapies unveiled in New Orleans. Diabzen, [S. l.], v. 4, n. 23, p. 46–47, 2026. Disponível em: https://thediabzen.com/index.php/d/article/view/66. Acesso em: 28 jul. 2026.